Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adrenomedullin for Prevention of Aggravation of Moderate COVID-19 Pneumonia (AM-P2-COVID2)
jRCT2071210038Phase 2Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in coronavirus pneumonia comparing Adrenomedullin arm with Placebo arm (2 arms). Primary endpoint: Period of oxygen administration. Started Jun 2021; status: recruiting.
02
Drugs
fispemifene
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on jRCT2071210038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210038.